a company, which engages in the discovery and development of monoclonal antibody-based therapeutics
Industry Biotechnology
A.I.dvisor tells us that MGNX and ANAB have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MGNX and ANAB's prices will move in lockstep.
Ticker / NAME | Correlation To MGNX | 1D Price Change % | ||
---|---|---|---|---|
MGNX | 100% | -6.55% | ||
ANAB - MGNX | 31% Poorly correlated | -5.28% | ||
NTLA - MGNX | 31% Poorly correlated | -3.65% | ||
FULC - MGNX | 31% Poorly correlated | -5.26% | ||
BHVN - MGNX | 30% Poorly correlated | -3.12% | ||
IOVA - MGNX | 30% Poorly correlated | -6.95% | ||
More |
Ticker / NAME | Correlation To MGNX | 1D Price Change % |
---|---|---|
MGNX | 100% | -6.55% |
monoclonal theme (2 stocks) | 90% Closely correlated | +3.35% |
drugs theme (265 stocks) | 21% Poorly correlated | +5.37% |
antibody theme (6 stocks) | 14% Poorly correlated | +3.08% |
biotechnology theme (248 stocks) | 6% Poorly correlated | +5.56% |